tb500 bpc 157 BPC-157/TB-500 Capsules BPC-157 + TB-500 Research Compound

We believe including the reference product's data in the blended calculation for a biosimilar's payment limit in the limited circumstance described could be appropriate in determining an operationally reasonable payment limit because the FDA approval for the biosimilar relies in part on FDA's previous determination of safety, purity, and potency for the reference product, and the biosimilar is necessarily approved for at least one condition of use that has been previously approved for its reference product, as required under the 351(k) approval pathway

(2019a)

FL: StatPearls

Beyond taste disturbances, tirzepatide may be associated with other oral and oropharyngeal symptoms that patients should be aware of, though these are not extensively documented in the prescribing information as common adverse effects